SRB 1
Alternative Names: SRB-1Latest Information Update: 18 Sep 2025
At a glance
- Originator SunRock Biopharma
- Class Anti-inflammatories; Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR9 receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Inflammation; Solid tumours
Most Recent Events
- 18 Sep 2025 Preclinical trials in Inflammation in Spain (Parenteral), prior to September 2025 (SunRock Biopharma pipeline, September 2025)
- 20 Dec 2023 Preclinical trials in Haematological malignancies in Spain (Parenteral) prior to December 2023 (SunRock Biopharma pipeline, December 2023)
- 20 Dec 2023 Preclinical trials in Solid tumours in Spain (Parenteral) prior to December 2023 (SunRock Biopharma pipeline, December 2023)